Cargando…

P1303: POTENTIATING ANTI-CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS

Detalles Bibliográficos
Autores principales:	Wiestner, A., Baskar, S., Peng, H., Gaglione, E., Lindorfer, M., Taylor, R., Rader, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431265/ http://dx.doi.org/10.1097/01.HS9.0000848076.05525.5e

Ejemplares similares

Monoclonal antibodies targeting cell surface deposited complement fragment C3d potentiate cancer immunotherapy and eliminate antigen loss variants
por: Skarzynski, Martin, et al.
Publicado: (2015)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
por: Lindorfer, Margaret A., et al.
Publicado: (2012)

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
por: Yang, Jiahui, et al.
Publicado: (2011)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
por: Oostindie, Simone C., et al.
Publicado: (2019)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Upgrading of high power klystron YK1303
por: Isagawa, S, et al.
Publicado: (1994)

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
por: Gui, Lin, et al.
Publicado: (2016)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody
Publicado: (1983)

Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody
por: Taji, Hirohumi, et al.
Publicado: (1998)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice
por: Smith, Mitchell R, et al.
Publicado: (2005)

Findings of a 1303 Korean whole-exome sequencing study
por: Kwak, Soo Heon, et al.
Publicado: (2017)

How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca(2+)
por: Taylor, Ronald P., et al.
Publicado: (2020)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

1303. Pelvic Acute Hematogenous Osteomyelitis in Children, from 2012-2020
por: Clemente, Adriana Sarmiento, et al.
Publicado: (2023)

Antibodies to CD20 and MHC class II antigen bound to B-lymphoma cells accumulate in shed cytoplasmic fragments
por: Michel, R B, et al.
Publicado: (2004)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis
por: Constantinides, Michael, et al.
Publicado: (2023)

Microbials for the production of monoclonal antibodies and antibody fragments
por: Spadiut, Oliver, et al.
Publicado: (2014)

Runs 1302 and 1303, 3.5 GeV/c Ring 2
por: Baird, S
Publicado: (1983)

Evaluation of DSD training schools organized by cost action BM1303 “DSDnet”
por: Bertalan, R., et al.
Publicado: (2018)

Fragment-based covalent ligand discovery
por: Lu, Wenchao, et al.
Publicado: (2021)

Covalent fragment inhibits intramembrane proteolysis
por: Eden, Angela, et al.
Publicado: (2022)

Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
por: McAulay, Kirsten, et al.
Publicado: (2022)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Luo, Chengxin, et al.
Publicado: (2021)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
por: Anderson, Annika, et al.
Publicado: (2023)

Anti-Lymphoma Efficacy Comparison of Anti-CD20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates
por: Lidický, Ondřej, et al.
Publicado: (2015)

Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using (213)Bi-Anti-CD20 Monoclonal Antibody
por: Havlena, Gregory T., et al.
Publicado: (2023)

Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies
Publicado: (1982)

FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis
por: Lindorfer, Margaret A., et al.
Publicado: (2022)

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
por: Naddafi, Fatemeh, et al.
Publicado: (2015)

Post-infectious Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Deposits Associated with Complement Factor H Mutation
por: Takehara, Eriko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aonncooiftvsah5d75d1qk0ibr